|
Raj, K P; Zell, J A; Rock, C L et al. (2013) Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer 108:512-8
|
|
Rial, Nathaniel S; Zell, Jason A; Cohen, Alfred M et al. (2012) Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Rev Gastroenterol Hepatol 6:507-17
|
|
Laukaitis, Christina M; Erdman, Steven H; Gerner, Eugene W (2012) Chemoprevention in patients with genetic risk of colorectal cancers. Colorectal Cancer 1:225-240
|
|
Zell, Jason A; Lin, Bruce S; Madson, Nikki et al. (2012) Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas. Cancer Causes Control 23:1739-44
|
|
Laukaitis, Christina M; Gerner, Eugene W (2011) DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol 25:495-506
|
|
Zell, Jason A; McLaren, Christine E; Chen, Wen-Pin et al. (2010) Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J Natl Cancer Inst 102:1513-6
|
|
Thompson, Patricia A; Wertheim, Betsy C; Zell, Jason A et al. (2010) Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 139:797-805, 805.e1
|
|
Gerner, Eugene W; Meyskens Jr, Frank L (2009) Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res 15:758-61
|
|
Zell, Jason A; Pelot, Daniel; Chen, Wen-Pin et al. (2009) Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 2:209-12
|
|
Meyskens Jr, Frank L; McLaren, Christine E; Pelot, Daniel et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32-8
|
Showing the most recent 10 out of 17 publications
